Hurth, Germany: Scientific findings from over 100 controlled clinical trials involving either cannabis or its constituents provide "clear evidence that cannabinoids are useful for the treatment of various medical conditions," according to a just published review in the German scientific journal Deutsches Ã„rzteblatt International. Investigators from the nova-Institute and the Hannover Medical School in Germany reviewed over 100 controlled trials assessing the safety and efficacy of cannabis and cannabinoids. Researchers reported: "Knowledge about the therapeutic potential of cannabis products has been greatly improved by a large number of clinical trials in recent years. ... There is now clear evidence that cannabinoids are useful for the treatment of various medical conditions," including chronic neuropathy (nerve pain), multiple sclerosis, HIV/AIDS, Gilles de la Tourette syndrome, and other indications. Regarding the safety profile of cannabis and cannabinoids, investigators determined: "The most common side effects of cannabinoids are tiredness and dizziness (in more than ten percent of patients), psychological effects, and dry mouth. Tolerance to these side effects nearly always develops within a short time. Withdrawal symptoms are hardly ever a problem in the therapeutic setting." Authors did express concern that cannabis could pose additional health risks for adolescents and/or pregnant or breast-feeding women, as well as individuals diagnosed with Hepatitis C, severe cardiovascular disease, addictive disorders, or those vulnerable to certain psychiatric disorders, such as schizophrenia. Investigators acknowledged that cannabis dosing may adversely impact psychomotor skills. However, they noted, "Patients who take cannabinoids at a constant dosage over an extensive period of time often develop tolerance to the impairment of psychomotor performance, so that they can drive vehicles safely." They concluded, "No acute deaths have been described that could be unequivocally attributed solely to cannabis consumption or treatment with cannabinoids." The paper is the second review in recent months rebutting the present Schedule I status of cannabis under federal law, which states that the plant and its organic constituents possess a "high potential for abuse," and that they lack "accepted medical use" and "accepted safety ... under medical supervision." Writing in The Open Neurology Journal this past May, investigators with the University of California at San Diego and the University of California, Davis concluded: "Evidence is accumulating that cannabinoids may be useful medicine for certain indications. Based on evidence currently available, the (federal) Schedule I classification (of cannabis) is not tenable; it is not accurate that cannabis has no medical value, or that information on safety is lacking." In 2011, the Obama administration -- via the United States Drug Enforcement Administration (DEA) -- formally denied a nine-year-old administrative petition filed by NORML and a coalition of public interest organizations calling on the agency to initiate hearings to reassess the present classification of marijuana as a schedule I controlled substance. In her denial of the petition, DEA administrator Michele Leonhart alleged: "[T]here are no adequate and well-controlled studies proving (marijuana's) efficacy; the drug is not accepted by qualified experts. ... At this time, the known risks of marijuana use have not been shown to be outweighed by specific benefits in well-controlled clinical trials that scientifically evaluate safety and efficacy." In June, Ms. Leonhart testified before Congress that she believed that heroin and marijuana posed similar threats to the public's health because, in her opinion, "all illegal drugs are bad." Coalition advocates are presently appealing the DEA's denial of their petition in federal court. For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, "The therapeutic potential of cannabis and cannabinoids" is available in the online edition of Deutsches Ã„rzteblatt International here: Deutsches Ã„rzteblatt international: The Therapeutic Potential of Cannabis and Cannabinoids (23.07.2012).